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Coronary artery calcification (CAC) is a heritable and definitive morphologic marker of atherosclerosis that strongly predicts risk for
future cardiovascular events. To search for genes involved in CAC, we used an integrative transcriptomic, genomic, and protein expres-
sion strategy by using next-generation DNA sequencing in the discovery phase with follow-up studies using traditional molecular
biology and histopathology techniques. RNA sequencing of peripheral blood from a discovery set of CAC cases and controls was
used to identify dysregulated genes, which were validated by ClinSeq and Framingham Heart Study data. Only a single gene, TREML4,
was upregulated in CAC cases in both studies. Further examination showed that rs2803496 was a TREML4 cis-eQTL and that the minor
allele at this locus conferred up to a 6.5-fold increased relative risk of CAC. We characterized human TREML4 and demonstrated by
immunohistochemical techniques that it is localized in macrophages surrounding the necrotic core of coronary plaques complicated
by calcification (but not in arteries with less advanced disease). Finally, we determined by von Kossa staining that TREML4 colocalizes
with areas of microcalcification within coronary plaques. Overall, we present integrative RNA, DNA, and protein evidence implicating
TREML4 in coronary artery calcification. Our findings connect multimodal genomics data with a commonly used clinical marker of
cardiovascular disease.Introduction
Coronary artery disease (CAD) is a leading cause of
morbidity and mortality.1 The pathogenesis of CAD in-
cludes lipid dysregulation and a local inflammatory
response, resulting in arterial atheromatous plaques.2,3
Advanced disease often includes plaque calcification,
which can be quantified by computed tomography
with coronary artery calcification (CAC) scoring.4 The
detection and quantification of CAC has high positive
predictive value for CAD events and can refine cardiovas-
cular risk estimates beyond that provided by standard
risk factors.4–6 High CAC scores (e.g., CAC score > 300)
are strong predictors of future CAD events.5 CAC is
highly heritable, suggesting a genetic basis, and candidate
genes have been sought by GWASs.7 However, only a
fraction of the genetic determination of CAC heritabil-
ity has been elucidated,8 and even for genes identified
through GWASs, such as the CDKN2A-CDKN2B locus
on 9p21 (MIM 600160 and 600431, respectively) and
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tive methodologies for identifying genes involved in
CAC. Specifically, we hypothesized that an integrated
multiomic and functional approach could identify genes
associated with CAC while also providing insight into
their biological role in this condition. First we used
peripheral blood transcriptome data from cases with
extreme CAC and matched controls as a screen to iden-
tify candidate dysregulated transcripts. We then validated
the expression phenotype in an independent cohort
by an orthologous technique. TREML4 (MIM 614664)
expression was positively associated with CAC in both
cohorts. Next, we used exome data to identify eQTL
SNPs for TREML4, followed by testing these SNPs for
concordance with CAC GWAS data. Finally, we character-
ized the candidate protein and its expression in calcified
coronary artery plaques from individuals with sudden
coronary death. Combining results from the above
RNA, DNA, and protein experiments, we suggest that
TREML4 may have a role in the formation of calcified
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Material and Methods
CAC Scoring
CAC scoring was performed by multislice computed tomography
(CT) (Aquilion One, Toshiba Medical Systems; Lightspeed VCT
or Lightspeed Ultra, General Electric Healthcare) using prospective
electrocardiographic gating and the Agatston scoring method.9
For ClinSeq, a single CT scan was performed; for the Framingham
Heart Study (FHS), the average CAC score from two sequential
scans was used. ClinSeq and FHS protocols for participant exami-
nation and collection of genetic materials were approved by the
NHGRI and Boston Medical Center Institutional Review Boards,
respectively. All ClinSeq subjects gave informed consent for
transcriptome and exome sequencing.
RNA Extraction, RNA-Seq Library Preparation,
Sequencing, and Data Analysis
Peripheral blood (2.5 ml) was drawn into PAXgene RNA tubes and
RNA extraction was done with the PAXgene Blood RNA Kit IVD
(QIAGEN). RNA-seq libraries were constructed from 1 mg of RNA
and sequencing was done on Illumina GAIIx sequencers, generating
two lanes of 76 bp reads for each library. Reads were aligned with
TopHat10 and the output file was converted to BED format with the
bamToBed script from the BEDTools package.11 The BEDTools cover-
ageBed script was used to derive read counts for individual exons in
the RefSeq database. A total count for each transcript in this database
was obtained by adding the counts for its constituent exons.
RNA-Seq Validation via Digital Multiplexed
Measurement of Gene Expression
To validate RNA-seq results, we used digital multiplexed measure-
ment of gene expression (DMMGE) (NanoString Technologies).12
Total RNA (120 ng) was used for each subject in conjunction with
the manufacturer’s standard protocol. Count data were normal-
ized with nSolver v.1.0 software and log10-transformed and a
two-level one-way ANOVA test was used to identify differentially
expressed genes.
Affymetrix Microarray Experiments for FHS Subjects
Total RNA (50 ng) from fasting peripheral whole-blood samples
(2.5 ml) were collected in PAXgene tubes (PreAnalytiX) and ampli-
fiedwith theWT-OvationPicoRNAAmplificationSystem(NuGEN)
using the Genechip Array Station (Affymetrix). Samples were run
onHuman Exon 1.0 STArrays (Affymetrix) according to themanu-
facturer’s protocol. Methods for RNA collection and microarray
analysis in the FHS Systems Approach to Biomarker Research
(SABRe) in CVD Initiative have been previously described.13
Microarray Data Analysis
The robust multichip average (RMA) method was applied to the
Affymetrix scanning data for normalizing expression values. After
adjusting for technical covariates, a standard linear mixed model
was used to analyze the data. CAC scores were natural log-trans-
formed. To account for family structure within the FHS cohort,
the R package ‘‘pedigreemm’’ was used, after modification to allow
for only one observation per participant.
Genotyping by Exome Sequencing and TaqMan PCR
Exomes of ClinSeq participants were sequenced as described previ-
ously.14 VarSifter software was used to isolate variants in TREML4Thexons. After identifying rs2803495 and rs2803496 as loci of
interest, subjects were genotyped for these loci via TaqMan SNP
Genotyping Assays (Life Technologies) on an Applied Biosystems
7900HT Fast Real-Time PCR System (Life Technologies). Geno-
types were exported into the JMP software suite for statistical anal-
ysis. For CAC GWAS meta-analysis, data from 9,992 subjects from
five CHARGE cohorts15 were used. Each CHARGE study excluded
all participants with any CACmeasure outside of52 standard de-
viations from the mean value. Results of the CAC meta-analysis
were previously reported.7
RT-PCR, Cloning, and Sanger Sequencing
Total RNA (1 mg) was reverse transcribed with the SuperScript III
First Strand cDNA kit (Life Technologies) with the gene-specific
primer 50-TGGATGTTTTACAAGAATACATTCAAA-30. PCR amplifi-
cation was performed with Platinum Taq polymerase (Life Tech-
nologies) and the following primers: 50-GCGTCTGACTCCTCC
TGAGA-30 (forward) and 50-GGAGGAAGGTGAGGGGATAC-30
(reverse). Amplicons were cloned with the TOPO TA Cloning Kit
(Life Technologies) and sequencedonABI 3730XLDNAsequencers
with BigDye Terminator v.3.1 chemistry (Life Technologies).
Immunohistochemical Staining
Formalin-fixed paraffin-embedded sections of human coronary fi-
broatheromas were incubated with a rabbit polyclonal antibody
reactive against TREML4 (dilution 1:800) after steam heat retrieval
in citrate buffer. Adjacent sections were immunostained with
the macrophage marker CD68 (dilution 1:800) after steam heat
retrieval in EDTA buffer. Primary antibodies were labeled with an
Envisionþ Kit (Dako) and developed with an ImmPACT NovaRED
Peroxidase Substrate System (Vector). Nuclei were counterstained
with hematoxylin (Dako). Positive control sections were from an
isolated human neutrophil pellet. Negative control staining was
achieved using nonimmune rabbit serum.
Measurement of TREML4 in Leukocyte
Subpopulations
Primary human leukocytes were isolated from blood obtained
from the National Cancer Institute-Frederick Research Donor
Program under a human subjects protocol approved by the NIH
Institutional Review Board. Informed consent was provided.
Peripheral mononuclear cells (PBMCs) were derived by centrifuga-
tion through Histopaque-1077 (Sigma). PBMCs were then centri-
fuged through Percoll (GE Healthcare) to separate lymphocytes
and monocytes. The monocyte layer was further purified with
the EasySep Negative Selection Monocyte Enrichment Kit (Stem
Cell Technologies). Neutrophils were purified by a custom
protocol.
Quantitative Real-Time PCR
Cells were resuspended in Trizol and RNA was extracted with the
RNeasy Mini Kit (QIAGEN) per the manufacturer’s instructions.
cDNAwas synthesized from total RNAwith the SuperScript III sys-
tem (Life Technologies). Quantitative RT-PCR was performed with
Taqman primer and probe sets on a 7300 Real-Time PCR system
(Life Technologies). Target genes were normalized to GAPDH.
TREML4 Polyclonal Antibody Design
Rabbits were immunized with two KLH-conjugated, TREML4-
derived peptides: aa 75–88 (cAVQKSHYTIWDKPN) and aa 157–
170 (cTSGHPSINGSETRK) (Epitomics). The resulting antiserae American Journal of Human Genetics 95, 66–76, July 3, 2014 67
reacted strongly with HEK293T expressing TREML4 but not with
parental HEK293. In addition, flow cytometric screens showed
reactivity with TREML4 with the CD8 leader but not TREML1 or
TREM1.
HEK293T Cell Culture
HEK293T cells were maintained in DMEM supplemented with
10% fetal bovine serum (FBS), 50 U/ml penicillin, 50 mg/ml strep-
tomycin, and 2mM L-glutamine. Constructs were introduced into
HEK293T cells with X-tremeGENE 9 transfection reagent (Roche)
according to the manufacturer’s instructions.
Immunoblotting
HEK293T cells were lysed in High Salt Lysis Buffer (50 mM Tris,
300 mM NaCl, 2 mM EDTA, 1% TTX-100) þ 0.4 mM Na3VO4,
aprotinin, leupeptin, and phenylmethylsulfonyl fluoride, and pro-
tein concentrations were determined with a BCA protein assay
(Pierce). Lysates were separated by SDS-PAGE and transferred
to PVDF membranes, followed by probing with the indicated
antibodies.
Flow Cytometry
HEK293Tcells were collected andwashed in PBSþ 0.1%BSA, 0.1%
sodium azide, and 2 mM EDTA. The samples were incubated with
the rabbit antisera, followed by phycoerythrin F(ab’) fragment
goat anti-rabbit IgG (HþL) (Life Technologies). Samples were
then read on an LSRFortessa flow cytometer (BD Biosciences).
RNA Blotting
Total RNA was extracted from human peripheral blood neutro-
phils with TRIzol (Life Technologies). A cDNA probe coding for a
portion of exon 2 through part of exon 5 of TREML4was amplified
by PCR with a human TREML4 full-length cDNA as a template.
The sequences for the primers were as follows: forward, 50-TCAC
CATGATTCAGCTGA-30; reverse, 50-AGGAGTCCACATAGCACC-
30. Total RNA (6 or 12 mg) were separated at 55V for 3 hr in a
1.2% agarose formaldehyde gel and blotted onto a nylon mem-
brane (Cole-Parmer). The membrane was hybridized at 42C over-
night in ULTRAhyb buffer (Life Technologies) with 106 dpm/ml of
the cDNA probe labeled by 32P (Perkin Elmer), washed twice with
23 SSC, 0.1% SDS for 15 min at room temperature and once with
0.13 SSC, 0.1% SDS for 30 min at 60C prior to autoradiographic
exposure to a XAR-5 X-ray film (Eastman Kodak) at 80C.Results
CAC Discovery and Experimental Design
This analysis included participants from two independent
CAD studies: ClinSeq and the FHS.16,17 In the ClinSeq
cohort, CAC was measured in 852 participants. We
selected 48 individuals with the highest CAC scores in
ClinSeq and matched each of these with an age-, gender-,
and ethnicity-matched control with zero CAC (Table S1
available online) to form two sets for transcriptome
profiling: 16 subjects (eight case:control pairs as the
screening set) for peripheral blood RNA-seq analysis and
a further 80 subjects (40 case: control pairs as the valida-
tion set) for RNA-seq validation via DMMGE, an orthog-
onal gene expression platform.12 The median CAC scores68 The American Journal of Human Genetics 95, 66–76, July 3, 2014for case subjects in the screening and validation sets were
1,531.5 and 668.5, respectively, whereas all control sub-
jects had a score of zero (Figure S1A). In the FHS, CAC
wasmeasured in 1,050 participants from the FHS Offspring
cohort;18 the median CAC score was 36, the first and third
quartiles were at 0 and 241, respectively, and the
maximum score was 4,951 (Figure S1B).
Transcriptome Screening by RNA-Seq, DMMGE, and
Expression Microarrays
We used transcriptome analysis as a screen to identify
candidate genes for further evaluation of association with
coronary artery calcification. RNA-seq comparison of case
and control subjects in the screening set showed 302 dys-
regulated genes at a liberal statistical cutoff one (one-way
ANOVA, p < 0.05 without correction for multiple testing,
fold change > 1.4) (Figure 1A; Table S2). Specific leukocyte
markers were not enriched in this list of 302 genes, suggest-
ing that variation in differential counts did not bias our
CAC case:control comparison. For 147 genes expressed
above the RNA-seq median in the screening set, we used
DMMGE to assess expression differences in the validation
set (Table S3). Of these 147 genes, 18 were dysregulated in
both sets (one-way ANOVA, p < 0.05 without correction
for multiple testing, fold change > 1.25; see Table S4 for
gene names). Next, these 18 genes were studied in existing
peripheral blood expression microarray data from FHS
Offspring participants with CAC scores.19 By using a
standard linear mixed-effects model, we found one gene
(TREML4) to be significantly upregulated with CAC in
both the ClinSeq and FHS cohorts (p < 0.05 without
correction for multiple testing). In addition to case:control
differential expression, we analyzed TREML4 expression as
a function of CAC scores by using linear regression in
the ClinSeq validation set. This showed a significant fit
(p < 0.001), associating increased TREML4 expression
with higher CAC scores (Figure 1B). In addition, TREML4
expression showed a bimodal distribution, suggesting the
presence of a cis-eQTL.
Peripheral Blood eQTLs for TREML4
Next, we explored the TREML4 locus for genomic variation
linked to differential expression. Using exome sequencing
data from the 96 subjects in the ClinSeq CAC screening
and validation cohorts, we detected seven heterozygous
variants located in TREML4 exons (Table S5). Of these var-
iants, a case:control comparison of genotype frequencies
showed that rs2803496, a C/T SNP in the 50 UTR, differed
significantly among the two groups (Pearson’s chi-square
test, p < 0.05 after multiple testing correction). Compari-
son of rs2803496 genotypes with TREML4 expression for
the 96 subjects from the ClinSeq screening and validation
sets showed that the heterozygous TC genotype was
strongly associated with increased TREML4 expression
(one-way ANOVA, p < 0.0001; Figure 1C). Because the
rare CC genotype (which had a population frequency of
~2% in the NHLBI ESP database) was absent in these 96
Figure 1. TREML4 Transcript Expression
and eQTL Analyses
(A) Volcano plot showing dysregulated
genes from RNA-seq ANOVA. Gray dots
show 160 genes chosen for DMMGE vali-
dation; red dots show 18 genes with p <
0.05 in validation cohort; green dot at bot-
tom right shows TREML4.
(B) Regression of TREML4 expression
(y axis) to CAC (x axis). Open circles, con-
trol subjects; filled circles, case subjects;
bold red line, linear regression slope;
curved red lines, 95% confidence intervals
for linear regression; green line, spline fit to
linear regression.
(C–E) eQTL analyses.
(C) TREML4 expression data for rs2803496
as measured by digital multiplexed mea-
surement of gene expression (DMMGE).
(D) qPCR TREML4 expression data for
rs2803496.
(E) DMMGE TREML4 expression data for
rs2803495.
The y axis in (C) and (E) shows the log10 normalized DMMGE TREML4 counts. The y axis in (B) shows qPCR quantification in groups of
five subjects from each genotype relative to a randomly chosen individual with a CT genotype. The tip of each green diamond represents
the 95% confidence interval and the center line in each diamond represents the group mean.subjects, we extended this experiment by identifying five
ClinSeq individuals with this genotype and then used
qPCR to study TREML4 expression in this group relative
to equal numbers of TC and TT individuals. We found
that the CC genotype conferred even higher TREML4
expression than TC (Figure 1D). Further, we also geno-
typed the ClinSeq cohort for rs2803495, the only other
common dbSNP variant (i.e.,R1%minor allele frequency)
in the 50 UTR of TREML4. Surprisingly, although rs2803495
and rs2803496 are located only 91 bp apart, they showed
very weak linkage disequilibrium (R2 ¼ 0.1 in the 1000 Ge-
nomes project,20 measured with the SNAP online tool).
Despite this absence of linkage of the two loci, rs2803495
showed eQTL characteristics as well, with presence of the
minor G allele being associated with higher TREML4
expression (one-way ANOVA, p ¼ 0.0016; Figure 1E).
Association of rs2803496 and Linked SNPs with
Calcification Scores
Given that rs2803495 and rs2803496 were TREML4 cis-
eQTLs and that TREML4 upregulation appeared to be asso-
ciated with CAC, we hypothesized that independently
from their effect on TREML4 expression, these genomic
variants would be associated with CAC scores in a larger
sample size than the initial 96-subject exome scan for
putative eQTLs. To test this hypothesis, we genotyped
both loci in 758 ClinSeq subjects for whom CAC scores
were available (Table S6) and calculated the relative risk
conferred by the C allele for different levels of CAC (see
Appendix S1 and Table S7). For rs2803496, the resulting
graph showed that presence of the C allele conferred a
steady progression in relative risk with increasing CAC
score thresholds, with the lower 95% confidence interval
rising above 1.0 at CAC> 200 and a relative risk maximum
of 6.5-fold for CAC > 1,200 (95% CI ¼ 1.94–21.73)Th(Figure 2). Genotypes at rs2803495 did not show any rela-
tionship with CAC relative risk, raising the chance that the
two eQTL SNPs are located on different haplotypes.
Next, we extended our SNP-based analyses to search for
GWAS support of the hypothesis that TREML4 is relevant
for CAC. Using SNAP, we identified five SNPs in strong link-
age disequilibrium (R2 > 0.8) with rs2803496 in the 1000
Genomes data (Table S8). These SNPs were then studied
in a fixed-effects meta-analysis of five CAC GWAS cohorts
in the CHARGE Consortium,7 modeling CAC scores as a
continuous trait. Two of the five SNPs (rs2253676 and
rs2627559), as well as rs2803496 itself, were found in the
combinedmeta-analysis data, all of which showed a consis-
tent directionof effect onCAC. Specifically, theminor allele
was associatedwith increased CAC scores independently in
eachof thefive cohorts for rs2803496 and rs2627559 and in
four of the five cohorts for rs2253676 (although the associ-
ation was marginally above significance, p ¼ 0.05–0.07)
(Table S9). In addition to this trend for increased CAC as a
continuous variable, for 3,057 FHS participants for whom
both CAC scores and rs2803496 genotypes were available,
theminor allele conferred an odds ratio of 1.34 for a dichot-
omous grouping of CAC¼ 0 andCAC> 100 (p¼ 0.04, 95%
CI 1.02–1.77, n at CAC > 100 ¼ 575).
Investigation of TREML4 Expression in Leukocyte
Subtype Populations
Because TREML4 dysregulation was detected by whole-
blood RNA and appeared to be controlled by cis-eQTLs, we
set out to identify the leukocyte subpopulations producing
TREML4 mRNA and the effect of the eQTLs on expression
in these subpopulations. We enriched subsets (>90%
pure) of leukocytes from human subjects of the five avail-
able rs2803495 and rs2803496 genotype combinations
and examined each by qPCR for levels of TREML4 mRNAe American Journal of Human Genetics 95, 66–76, July 3, 2014 69
Figure 2. Relative Risk of CAC at Different Thresholds Conferred
by the Minor C Allele at rs2803496
Vertical bars show lower 95% confidence interval at each data
point.
Figure 3. qPCR Experiment for TREML4 Expression in Leukocyte
Populations
The y axis shows fold change relative to GAPDH. The x axis shows
the rs2803495/rs2803496 genotypes for each subject (the com-
bined homozygous minor condition GG/CC was not found in
any subject). Five subjects from each genotype combination
were tested; mean values were used for graphing. Error bars repre-
sent standard deviations.(no donors were found with the combination of rareminor
homozygous stateGG/CC) (Figure 3). Lymphocytes had lit-
tle to no expression, regardless of genotype, whereasmono-
cytes had low-level expression that significantly increased
with the presence of either a G allele for rs2803495 and/or
C allele for rs2803496. However, neutrophils by far ex-
pressed the most TREML4 and, like the monocytes, had
significantly higher levels with the presence of a G allele
for rs2803495 and/or C allele for rs2803496.
Validation of TREML4 as a Protein-Coding Gene
The human TREM family has not yet been extensively
characterized,21 and TREML4 in particular has not been
studied beyond gene annotation. Hence, we set out to
validate the protein-coding ability of this gene. RT-PCR
using peripheral blood RNA and primers placed on the
50 and 30 UTRs showed three bands (Figure 4A), which
were cloned and sequenced. All three amplicons mapped
to the TREML4 locus and consisted of distinct sets of
exons spliced together without any intronic sequence
(consistent with the RNA-seq data at this locus, which
showed multiple gapped reads connecting these exons).
When sequences of the three amplicons were translated,
one contained a complete open reading frame, linking
exons 1–6 into a 200 aa polypeptide (Figure 4A). Because
the TREML4 locus showed some intronic and intergenic
RNA-seq expression, we confirmed the size of the spliced
transcript by an RNA blot on neutrophil RNA, with
a cDNA probe targeting a segment from exon 2 to part
of exon 5. We observed two bands in the region of
the 2.4 kb marker (Figure 4B), consistent with the
ENST00000341495 and ENST00000461240 variants of70 The American Journal of Human Genetics 95, 66–76, July 3, 2014TREML4 (2,070 bp and 2,304 bp, respectively) reported
in the Ensembl database.
In contrast to the predicted molecular configuration of
murine TREML4, the humanpolypeptide sequence showed
a conservedV-Set Ig domain and stalk and a truncated trans-
membrane domain.22 Also, TREML4 has a relatively short
(~10 aa), noncanonical leader sequence that includesmulti-
ple cysteines. Hence, we set out to confirm that this gene
produces an actual protein. We generated two TREML4
cDNA constructs, both containing the FLAG epitope23
with either the CD8 leader sequence or the native TREML4
leader sequence, respectively, which were then transfected
into HEK293T cells. Using flow cytometry with the anti-
FLAG antibody, we found no cell surface FLAG reactivity
in the transfectantswith thenative leader, but good cell sur-
face expression for cDNA with the CD8 leader (Figures 4C
and 4D). These data suggest that if the receptor is properly
inserted into the membrane for expression on the cell sur-
face, then the truncated transmembrane domain is capable
of anchoring it there. In contrast, the native leader appears
incapable of facilitating surface expression of TREML4.
Immunoblotting of lysates from similarly transfected
HEK293T cells showed that TREML4 with the native leader
sequence had an apparently low molecular weight compa-
rable to the predicted mass of the core polypeptide
(Figure 4E). On the other hand, cells transfected with the
CD8 leader construct showed strong reactivitywith a larger,
moreheterogeneousbandconsistentwithposttranslational
processing during expression on the cell surface. We also
made a polyclonal antibody specific to TREML4, which
gave similar results to that of the anti-FLAG antibody.
TREML4 Localization in Atherosclerotic Lesions
Finally, we hypothesized that if TREML4 is relevant for
CAC and/or CAD, then the protein would be present in
atherosclerotic lesions. To test this, we used the polyclonal
anti-TREML4 antibody for immunohistochemical staining
Figure 4. Validation of TREML4 as a Protein-Coding Gene
(A) RT-PCR results showing three bands for TREML4. Abbreviations are as follows: PB, peripheral blood; PMN, polymorphonuclear
neutrophils; gDNA, genomic DNA; HaeIII, ladder with HaeIII-digested 4x174 DNA (bands: from top, 1,353 bp, 1,072 bp, 872 bp,
603 bp); red star shows amplicon with uninterrupted CDS, alignment to TREML4 locus on chromosome 6 shown in lower panel.
(B) RNA blot results: left panel shows PMN RNA before probing, right panel shows bands for TREML4 after 25 hr exposure (black arrows)
next to 2.4 kb marker band.
(C and D) Flow cytometry results from TREML4 construct with artificial CD8 leader sequence and FLAG tag showing detection on surface
of HEK293 cells by aFLAG antibody (C) and anti-TREML4 antibody (D).
(E) Immunoblot results showing the larger protein from a construct with artificial leader sequence and smaller protein from construct
with natural leader sequence. Mock transfection with vector only was used as control.of coronary artery sections from human subjects with sud-
den cardiac death. We found distinct immunoreactivity to
TREML4 in lesional macrophages within the fibrous cap
and in areas bordering the necrotic core (Figures 5A–5F).
Immunostaining with the macrophage marker CD68
confirmed the presence of macrophage cells in areas
stained by TREML4. As a nondisease control, we stained
sections of coronary arteries from the same subjects but
from regions with adaptive intimal thickening. These did
not stain for TREML4, except in luminal endothelial cells
of the adventitial vasa vasorum, which showed a strong
positive reaction (Figures 5G–5I). Further, calcification-spe-
cific staining with the von Kossa stain showed regions ofThmicrocalcification in segments of the lesion positive for
TREML4 (Figures 6A and 6B). Lastly, by using dual immu-
nofluorescence staining for TREML4 and the CD68, we
found a distinctive pattern for colocalization of TREML4
with inflammatory macrophages in foam cell regions of
the plaque (Figure 6C). TREML4 was not detected in non-
foam-cell areas of the same plaques (Figure 6D).Discussion
Despite its widespread use as a clinical predictor of
atherosclerotic CAD events, the genetic basis of CAC is stille American Journal of Human Genetics 95, 66–76, July 3, 2014 71
Figure 5. TREML4 Localization in Human Coronary Atheroma
(A) Human coronary fibroatheroma with calcification, Movat pentachrome stain. The red area in the central lumen is the postmortem
clot.
(B) A high-power magnification of the area within the black box in (A) showing a necrotic core (NC) rich in free cholesterol with an
overlying thin fibrous cap (FC) infiltrated by inflammatory cells.
(C) Immunostaining with the macrophage marker CD68 shows extensive reactivity in the fibrous cap and surrounding necrotic core.
(D) Immunostaining with a rabbit polyclonal antibody targeted against TREML4 is strongly positive in the superficial region of the
fibrous cap and perinecrotic core (inset).
(E) A high-power magnification of region shown in (D) shows intense TREML4 staining of inflammatory cells bordering the luminal
space.
(F) The adjacent histologic section immunostained with nonspecific anti-rabbit antisera shows negative staining.
(G) A control artery from the same patient exhibiting adaptive intimal thickening, Movat pentachrome stain.
(H) A high-power view of the section in (G) shows negative staining for TREML4 (A, tunica adventitia; M, tunica media; and I, tunica
intima).
(I) The same section as (G) showing positive staining for TREML4 in adventitial vasa vasorum.
Scale bars represent 500 mm (A); 100 mm (B–D, F); 200 mm (G); 20 mm (H); or 10 mm (insets in D, E, I).poorly understood.24,25 Currently, the few genes unambig-
uously implicated in arterial calcification such as ABCC6
(MIM 603234), ENPP1 (MIM 173335), and NT5E (MIM
129190) have been detected through analysis of individ-
uals with ultrarare phenotypes25,26 whereas at the other
end of the frequency spectrum, GWAS candidate loci
have strong statistical evidence but limited biological con-
tinuity from SNP variants to lesional pathophysiology.27,28
As an alternative to these approaches, we describe here an
unbiased series of experiments (Figure 7) that started out as
a case:control transcriptome screen by RNA-seq to identify
dysregulated genes in CAC, and then progressively moved
into the genome and the proteome for deeper characteriza-
tion of TREML4, the best transcriptome candidate. Succes-
sive experiments in this integrative approach consistently72 The American Journal of Human Genetics 95, 66–76, July 3, 2014supported the hypothesis that TREML4 is involved in
CAC, in the process bridging the gap between multimodal
clinical genomics data and a CAD risk biomarker. Given
the current exponential growth of next-generation DNA
sequencing (NGS) applications in clinical and translational
research, we suggest that our methodology, which started
with NGS as a screening tool and was subsequently
extended to traditional biological techniques for rigorous
validation of NGS findings, offers an alternative to GWASs
and rare-variant analyses as an approach for clinical gene
discovery.
Functionally, TREMgenes act asmodulators of the innate
immune response, either by amplification or dampening of
toll-like receptor signals.21,29,30 As a consequence, this fam-
ily has a role in fine-tuning of inflammatory responses, and
Figure 6. Colocalization of TREML4
Staining with Microcalcification and
Foamy Macrophages within Atheroscle-
rotic Lesions
(A) Carotid plaque stained with calcifica-
tion-specific von Kossa stain showing re-
gions of calcification (black circles).
(B) Same section stained with TREML4
antibody.
(C) Foam cell region of carotid plaque
analyzed by dual immunofluorescence
staining with macrophage-specific CD68
marker (box 2) and TREML4 antibody
(box 3); overlapping the images shows co-
localization (box 4).
(D) Same procedures as (C) show no stain-
ing in non-foam-cell areas of the same
plaque.hence the association of TREML4 with an inflammation-
associated phenotype such as CACmight not be surprising.
Indeed, TREML4 would be the third CAD-associated gene
out of five in the TREM cluster. A common variant in
TREM2 (MIM 605086) has recently been associated with
C-reactive protein levels,31 and in cultured foam cells,
TREM1 (MIM 605085) is a positive regulator of the recog-
nized atherogenic cytokines TNF-a and IL-8.32 For TREML1
(MIM 609714), although a direct relationship to CAD has
not been shown, this gene promotes platelet aggrega-
tion,33 a crucial component of atherosclerotic plaque
development. Outside of CAD, TREM2 is associated with
Alzheimer disease, another inflammation-related syn-
drome.34,35 Our finding of a role for TREML4 in cardiovas-
cular disease is also supported by prior studies that identi-
fied it as a candidate for poststenotic collateral coronary
artery development36 and as one of 13 genes with elevated
peripheral blood mRNA expression in individuals with
early presentation of acute coronary syndromes.37 Taken
together, these data suggest that the TREM family is a candi-
date locus for various human inflammatory phenotypes,
and even more specifically, for CAD outcomes. Gene
expression changes can sometimes be reactive to a patho-
genic state as opposed to causative. In this context, it is
important to emphasize that the genomic association of
the rs2803496 TREML4 eQTL with CAC (independent of
transcript levels) in both the ClinSeq and FHS cohorts sug-
gests against increased TREML4 expression being reactive
relative to the onset of calcification. However, given that
controls with zero CAC can also have very high TREML4
expression levels (Figure 1B), and the peak of the relative
risk conferred by the eQTL SNP is found at high CAC levels,The American Journal of Hwe hypothesize that TREML4 func-
tions as a modifier that plays a role in
converting soft plaque to calcified pla-
que rather than being causative for the
presence of plaque itself.
Our data suggest a number of possi-
bilities for functional links of TREML4
to CAC. By using a newly developedantibody against TREML4, we found it to be localized in le-
sional macrophages bordering the necrotic core within
advanced coronary plaques. In this regard, our data again
point to apossible connectionof TREML4 to atherosclerotic
lesions, considering the importance ofmacrophage infiltra-
tion and lesion necrosis in plaque progression and vulnera-
bility.38 Moreover, given the widening perspective that
TREM genes are pluripotent modifiers of inflammation,
ourdata suggest a linkbetween the expressionof proinflam-
matory mediators and upregulation of osteogenesis-associ-
ated factors through activation of Toll receptors, whereby
TREML4 could play a role in coronary calcification.39,40
Further possibilities for TREML4 to be involved in the path-
ogenesis of coronary atherosclerosis come from the docu-
mented function of its murine homolog, which binds
apoptotic or necrotic cells.22 If human TREML4 has a
similar binding ability, its function within atherosclerotic
lesions could be related to the extensive apoptosis that
accompanies advanced CAD.41,42 Although the failure of
the TREML4 natural leader sequence to direct the protein
to the cell membrane argues against the last hypothesis,
elevated levels of TREML4 observed in advanced coronary
plaques (particularly in necrotic regions) suggest its po-
tential involvement in macrophage cell death, possibly
through alternative mechanisms to its murine homolog.
Given the large excess of TREML4 in neutrophils
compared to other leukocytes, it is also possible that
involvement inCADcouldbemediated through these cells.
Previous studies have shown widespread coronary neutro-
phil activation in individuals with unstable angina.43,44
Along the same lines, circulating myeloperoxidase
(a hemoprotein stored in azurophilic granules and releaseduman Genetics 95, 66–76, July 3, 2014 73
Figure 7. Flow Diagram of IntegrativeMethodology for Propos-
ing Association with CACupon neutrophil activation) has predictive value for out-
comes of acute coronary syndrome and is considered
a marker of plaque vulnerability.45–47 Similarly, TREML4
(which does not appear to be a surface receptor) could
be stored in neutrophil granules and, along with other
granule proteins, be similarly discharged in response to
cell activation.
In suggesting that TREML4 is associated with CAD, it
is important to acknowledge the limitations of this study.
Our differential gene expression results were used as a
screen and did not reach statistical significance after multi-
ple test correction. However, we sought to overcome this
by requiring not only analyses in two different CAC studies74 The American Journal of Human Genetics 95, 66–76, July 3, 2014but also by constraining the proposed association to need
additional support at the DNA and protein levels. The pre-
vious finding of TREML4 upregulation in peripheral blood
of individuals with acute coronary syndrome also supports
our conclusions.37 We recognize that subjects with zero
CAC may also have high TREML4 levels. This is consistent
with the complex etiology of CAD, which involves combi-
nations of risk factors and gene-environment interactions.
We cannot conclude that TREML4 is a primary cause of
necrotic calcified atherosclerotic lesions. Instead, we sug-
gest that it is one component of risk for disease, if other
risks are present. Atypical features of TREML4 such as
its short leader sequence and truncated transmembrane
domain raise questions regarding its mode of action. If it
is not a canonical receptor, the functional mechanism
may involve either protein misfolding48 or extracellular
secretion of TREML4. The latter hypothesis is particularly
appealing, because other TREM genes are known to pro-
duce biologically active secreted isoforms with either
agonist or antagonist activities.33,49,50
In conclusion, we present an integrative methodology
for disease gene discovery and demonstrate the use of
this methodology to find a new genetic association with
CAC. Data for the proposed association come from the
transcriptome, genome, and proteome; all of these support
an involvement of TREML4 in CAD. Overall, our findings
are in agreement with the hypothesis that inflammation
contributes to the formation of advanced, severe athero-
sclerotic lesions.Supplemental Data
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